GET DAILY SIGNALSWhy Is Arcutis Biotherapeutics (ARQT) Stock Down -17.83% Today?
Key Takeaways
- Shares plunged 17.83% to $27.98, down from the prior session's close of $34.05.
- Primary catalyst: Third-quarter earnings missed Wall Street's bottom-line estimate, with EPS of $0.06 versus a consensus of $0.18.
- Secondary driver: Despite the EPS miss, revenue of $143.9 million beat estimates and full-year guidance was raised to $535–$545 million, which was not enough to offset the earnings-driven selloff.
- Broader context: The decline reflects an earnings-driven repricing in the medical dermatology and biotech space rather than a broad-market correction.
- What traders are watching next: Fourth-quarter revenue momentum, guidance execution, and pipeline readouts including the hidradenitis suppurativa Phase 2 data expected in early 2027.
- For more detail on Price Targets, Earnings, and Forecast, explore Tickeron's dedicated pages.
- Explore the latest Trending AI Robots to see which AI-driven trading strategies are performing under current market conditions.
Opening Summary
Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage medical dermatology company best known for its lead product ZORYVE (roflumilast), saw its shares drop sharply in Thursday's trading. The stock fell 17.83% to $27.98, down from a prior close of $34.05. The move was a clear, decisive decline, and markets attributed it primarily to a third-quarter earnings report that missed analyst expectations on the bottom line, even as revenue and full-year guidance came in ahead of forecasts.
Earnings Results and Guidance
The dominant catalyst behind the selloff was Arcutis's third-quarter earnings release. The company reported adjusted earnings per share of $0.06, well short of the $0.18 consensus estimate, representing an earnings surprise of roughly -65%. On the top line, however, the company delivered $143.9 million in revenue, modestly beating the $141.94 million consensus and marking strong year-over-year growth from approximately $99.2 million a year earlier.
Management also raised its full-year 2026 revenue guidance to a range of $535 million to $545 million, up from the prior midpoint of roughly $525–$540 million. Despite the revenue beat and the raised outlook, investors focused on the magnitude of the EPS shortfall, and the stock's sharp decline suggests the market was already pricing in stronger profitability.
Market Reaction and Trading Activity
The price action reflected a classic earnings-driven repricing. Trading volume in recent sessions had already been running around one million shares per day, and the post-earnings move extended losses that began in the after-hours session immediately following the report, when shares initially fell toward the low $29 range. Thursday's continued slide to the high $27 area showed sustained selling pressure rather than a brief, isolated dip.
The move appeared to be company-specific rather than sector-wide. Arcutis's decline was driven by its own results rather than a broad rotation out of biotech or medical dermatology peers, underscoring that the catalyst was idiosyncratic to the company's quarterly performance.
What Comes Next for ARQT
Investors will now turn their attention to execution on the company's ZORYVE franchise and its ability to translate strong revenue growth into consistent profitability. Key items ahead include fourth-quarter revenue trends, further progress on the company's "Grow, Expand, Build" strategy, and pipeline developments, including the Phase 2 proof-of-concept readout for the hidradenitis suppurativa program expected late in the first quarter of 2027.
Risks remain. The company's premium valuation relative to peers leaves it exposed to further multiple compression if profitability underwhelms, while competition in the branded non-steroidal topical dermatology segment and clinical development uncertainties continue to pose challenges. Traders will be watching whether analysts revise estimates downward following the EPS miss, and whether the raised revenue guidance can restore confidence over the coming quarters.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots covering thousands of tickers. While Tickeron offers hundreds of automated strategies, only the strongest performers under current market conditions are featured in this section, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see which AI robots are currently generating the most notable results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARQT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARQT turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 41 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ARQT as a result. In 75 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +8.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 198 of 222 cases where ARQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 59 of 69 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ARQT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.385) is normal, around the industry mean (2.904). ARQT has a moderately high P/E Ratio (122.727) as compared to the industry average of (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology
Advertisement